Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BOLD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: A cost-effectiveness evaluation of 3 abtimicrobial regimens for the prevention of infective complications after abdominal surgery, Gillian Anderson, Cathrenine Boldiston, Simon Woods, Paul O´Brien, Arch Surg/Vol 131, July 1996A cost-effectiveness evaluation of 3 abtimicrobial regimens for the prevention of infective complications after abdominal surgery, Gillian Anderson, Cathrenine Boldiston, Simon Woods, Paul O´Brien, Arch Surg/Vol 131, July 1996
    Active substance: CEFOTAXIME
    Study summary document link (including results):
    View full study record
    Document reference: 23461
    Study title: Treatment of arthritis with topical capsaicin: a double−blind trial. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F. Clinical therapeutics, May−Jun 1991, vol. 13, no. 3, p. 383−95.Treatment of arthritis with topical capsaicin: a double−blind trial. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F. Clinical therapeutics, May−Jun 1991, vol. 13, no. 3, p. 383−95.
    Active substance: CAPSAICIN
    Study summary document link (including results):
    View full study record
    Document reference: 23225
    Study title: Intraoperative use of the mobile gamma camera in localizing and excising osteoid osteomas of the spine. Osebold WR, Lester EL, Hurley JH, Vincent RL. Spine. 1993 Oct 1;18(13):1816-28.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43648
    Study title: Nepola JV, Seabold JE, Marsh JL, Kirchner PT, el-Khoury GY. Diagnosis of infection in ununited fractures. Combined imaging with indium-111-labeled leukocytes and technetium-99m methylene diphosphonate. J Bone Joint Surg Am. 1993 Dec;75(12):1816-22. Nepola JV, Seabold JE, Marsh JL, Kirchner PT, el-Khoury GY. Diagnosis of infection in ununited fractures. Combined imaging with indium-111-labeled leukocytes and technetium-99m methylene diphosphonate. J Bone Joint Surg Am. 1993 Dec;75(12):1816-22.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43644
    Study title: Evaluation of temporal and facial osteomyelitis by simultaneous In-WBC/Tc-99m-MDP bone SPECT scintigraphy and computed tomography scan. Weber PC, Seabold JE, Graham SM, Hoffmann HH, Simonson TM, Thompson BH. Otolaryngol Head Neck Surg. 1995 Jul;113(1):36-41.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43594
    Study title: Postoperative bone marrow alterations: potential pitfalls in the diagnosis of osteomyelitis with In-111-labeled leukocyte scintigraphy. Seabold JE, Nepola JV, Marsh JL, Hawes DR, Justin EP, Ponto JA, Pettit WA, el-Khoury GY, Kirchner PT. Radiology. 1991 Sep;180(3):741-7.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44265
    Study title: Cranial osteomyelitis: diagnosis and follow-up with In-111 white blood cell and Tc-99m methylene diphosphonate bone SPECT, CT, and MR imaging. Seabold JE, Simonson TM, Weber PC, Thompson BH, Harris KG, Rezai K, Madsen MT, Hoffman HT. Radiology. 1995 Sep;196(3):779-88.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44260
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 10:16:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA